Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering

Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering

Copyright 1999 Academic Press.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 92(1999), 3 vom: 15. Sept., Seite 276-84
1. Verfasser: Meroni, L (VerfasserIn)
Weitere Verfasser: Fusi, M L, Varchetta, S, Biasin, M, Rusconi, S, Villa, M L, De Vries, J E, Aversa, G, Galli, M, Clerici, M
Format: Aufsatz
Sprache:English
Veröffentlicht: 1999
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antigens, CD Cytokines Gene Products, env Glycoproteins Immunoglobulins Peptides Receptors, Cell Surface mehr... Signaling Lymphocytic Activation Molecule Family Member 1 169535-43-7 Interferon-gamma 82115-62-6
LEADER 01000naa a22002652 4500
001 NLM10410631X
003 DE-627
005 20231222131816.0
007 tu
008 231222s1999 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0347.xml 
035 |a (DE-627)NLM10410631X 
035 |a (NLM)10479532 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Meroni, L  |e verfasserin  |4 aut 
245 1 0 |a Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering 
264 1 |c 1999 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 18.10.1999 
500 |a Date Revised 24.11.2016 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 1999 Academic Press. 
520 |a Signaling lymphocytic activation molecule (SLAM) is a transmembrane lymphocytic receptor which gets rapidly upregulated following cell activation. SLAM engagement augments T cell expansion and interferon-gamma (IFN-gamma) production independently of CD28. SLAM signaling is regulated by the SLAM-associated protein. We evaluated the expression and function of SLAM on CD4(+) and CD8(+) lymphocytes in HIV-infected individuals with either recently acquired infection (Group A) or asymptomatic HIV infection (Group B) and in healthy controls (HC). Soluble antigen (HIV env peptides and tetanus toxoid)- and mitogen-stimulated proliferation and IFN-gamma and IL-10 production upon SLAM costimulation were also measured. Results showed that: (1) SLAM-expressing CD4(+) and CD8(+) lymphocytes diminish in group A patients compared to both group B patients and HC; (2) SLAM expression on CD4(+) lymphocytes is preferentially associated with the lack of CD7 on cell surface (CD4(+)CD7(-) produce IL-10 but not IFN-gamma); (3) SLAM engagement increases HIV env peptide-stimulated, but neither tetanus toxoid- nor PHA-stimulated proliferation of peripheral blood mononuclear cells (PBMC) in patients but not in HC; and (4) SLAM engagement augments IFN-gamma and reduces IL-10 production by env peptide-stimulated PBMC of HIV-infected individuals. These results demonstrate that early HIV infection results in an altered SLAM expression which correlates with a time-limited impairment of cell-mediated immunity. Furthermore, they show that triggering via SLAM potentiates HIV-specific proliferative responses with simultaneous downregulation of IL-10 and redirection of the response to TH0/TH1 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Gene Products, env  |2 NLM 
650 7 |a Glycoproteins  |2 NLM 
650 7 |a Immunoglobulins  |2 NLM 
650 7 |a Peptides  |2 NLM 
650 7 |a Receptors, Cell Surface  |2 NLM 
650 7 |a Signaling Lymphocytic Activation Molecule Family Member 1  |2 NLM 
650 7 |a 169535-43-7  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
700 1 |a Fusi, M L  |e verfasserin  |4 aut 
700 1 |a Varchetta, S  |e verfasserin  |4 aut 
700 1 |a Biasin, M  |e verfasserin  |4 aut 
700 1 |a Rusconi, S  |e verfasserin  |4 aut 
700 1 |a Villa, M L  |e verfasserin  |4 aut 
700 1 |a De Vries, J E  |e verfasserin  |4 aut 
700 1 |a Aversa, G  |e verfasserin  |4 aut 
700 1 |a Galli, M  |e verfasserin  |4 aut 
700 1 |a Clerici, M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 92(1999), 3 vom: 15. Sept., Seite 276-84  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:92  |g year:1999  |g number:3  |g day:15  |g month:09  |g pages:276-84 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 92  |j 1999  |e 3  |b 15  |c 09  |h 276-84